-
Eagle Pharmaceuticals (EGRX) PT Raised to $84 at RBC Capital
-
Eagle Pharmaceuticals, Inc. to Present at 2018 RBC Capital Markets Global Healthcare Conference
-
Eagle Pharmaceuticals (EGRX): Starting To Look LIke A 2019 Story - RBC
-
Eagle Pharmaceuticals (EGRX) PT Lowered to $81 at RBC Capital; Reiterates Outperform
-
RBC Capital Reiterates Outperform Rating and $86 PT on Eagle Pharmaceuticals (EGRX); 'Focus Shifting to Ryanodex EHS"
-
Eagle Pharmaceuticals to Present at 2017 RBC Capital Markets Global Healthcare Conference
-
RBC Capital Cuts Price Target on Eagle Pharmaceuticals (EGRX) to $86; Reiterates Outperform
-
Eagle Pharmaceuticals (EGRX): Analyst Day Takeaway - RBC
-
Notable Mergers and Acquisitions 11/11: (VNTV) (EGRX) (DSGX)
-
Eagle Pharmaceuticals (EGRX): Raising PT After Surprise News But Ahead Of Analyst Day - RBC
-
Eagle Pharmaceuticals (EGRX): Notes From Management Meetings - RBC
-
Eagle Pharmaceuticals (EGRX): Setup Looks Attractive - RBC
-
TREANDA Ruling Positive for Eagle Pharma (EGRX) and Teva (TEVA); Removes Huge Uncertainty for EGRX - RBC
-
Eagle Pharma (EGRX) Sell Off Overdone - RBC
-
Unusual 11 Mid-Day Movers 3/18: (ECR) (NWY) (MNKD) Higher; (HTBX) (CBAY) (EGRX) Lower
-
Eagle Pharmaceuticals to Present at RBC Capital Markets 2016 Global Healthcare Conference
-
RBC Capital Sees Potential for Further Upside on Eagle Pharmaceuticals (EGRX) - Reiterates Outperform
-
Notable Analyst Rating Changes 12/9: (INTC) (A) (CSC) Upgraded; (SXC) (JBL) (NCLH) Downgraded
-
Notable Analyst Rating Changes 6/22: (MET) (PGR) (SNDK) Upgraded; (ALL) (SYMC) (PLCM) Downgraded
-
RBC Capital Starts Eagle Pharmaceuticals (EGRX) at Outperform
-
Eagle Pharmaceuticals (EGRX) 1.3M Offering Priced at $42/Share
-
Eagle Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Eagle Pharmaceuticals (EGRX) Commences $50M Stock Offering
-
Eagle Pharmaceuticals Announces Commencement of Public Offering of Common Stock

